Glutamate receptor ionotropic, NMDA 1 (GluN1) glycine binding site (GluN1 glycine site)

The NMDA receptor glycine co-agonist site is a critical regulatory locus located on the GluN1 (also known as NR1) subunit of the N-methyl-D-aspartate (NMDA) receptor complex (UniProt P17342) [1]. Unlike the glutamate-binding site found on the GluN2 subunits, this site must be occupied by glycine or D-serine for the ion channel to open, making these molecules essential co-agonists for excitatory neurotransmission (PMID: 11518769) [2]. This site plays a fundamental role in modulating synaptic plasticity and long-term potentiation, which are the cellular hallmarks of learning and memory (PMID: 20378761) [3]. In clinical pathology, hypofunction of the NMDA receptor via this glycine site is strongly implicated in the cognitive and negative symptoms of schizophrenia (PMID: 12735341) [4]. Conversely, overactivation of the receptor can lead to excitotoxic neuronal death, a process involved in ischemic stroke and various neurodegenerative diseases. Pharmacological targeting of the GluN1 glycine site includes the use of agonists or partial agonists, such as D-cycloserine and rapastinel, to enhance NMDA receptor signaling for treating depression and cognitive deficits (PMID: 21070804) [5]. Antagonists like gavestinel and licostinel have also been developed to provide neuroprotection by preventing excessive calcium influx during acute brain injury. The site is distinct from the polyamine and magnesium binding sites, offering a specific target for fine-tuning glutamatergic tone without the total blockade associated with channel-pore inhibitors.

Other names

NR1 glycine siteGlycine-B siteNMDA receptor glycine siteGRIN1 glycine binding siteNMDA receptor glycine co-agonist site

The GluN1 subunit contains a mandatory co-agonist binding site that must be occupied by glycine or D-serine to allow the NMDA receptor channel to open upon glutamate binding (PMID: 11518769). Drugs targeting this site act as agonists or partial agonists to enhance NMDA receptor function for pro-cognitive or antidepressant effects, or as competitive antagonists to reduce excitotoxic calcium influx (PMID: 20378761).